[go: up one dir, main page]

WO2003038439A3 - Functional identification of targets on tissues and cells - Google Patents

Functional identification of targets on tissues and cells Download PDF

Info

Publication number
WO2003038439A3
WO2003038439A3 PCT/EP2002/012215 EP0212215W WO03038439A3 WO 2003038439 A3 WO2003038439 A3 WO 2003038439A3 EP 0212215 W EP0212215 W EP 0212215W WO 03038439 A3 WO03038439 A3 WO 03038439A3
Authority
WO
WIPO (PCT)
Prior art keywords
molecules
disease
cytotoxicity
animal
human cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/012215
Other languages
French (fr)
Other versions
WO2003038439A2 (en
Inventor
Jens Hain
Bergen Martin Von
Thomas Marti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MEGAMEDICS GmbH
Original Assignee
MEGAMEDICS GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MEGAMEDICS GmbH filed Critical MEGAMEDICS GmbH
Priority to EP02777339A priority Critical patent/EP1634080A2/en
Publication of WO2003038439A2 publication Critical patent/WO2003038439A2/en
Publication of WO2003038439A3 publication Critical patent/WO2003038439A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a method for the identification of disease-specific molecules of animal or human cells comprising (a) identifying body fluids from animals or humans not affected by said disease which are cytotoxic for animal or human cells carrying disease-specific molecules; (b) incubating fractions of said animal or human cells carrying disease specific molecules with cytotoxic body fluids from animals or humans not affected by said disease identified in step (a) and with said animal or human cells carrying disease specific molecules; (c) identifying fractions that interfere with the cytotoxicity of said body fluids towards said animal or human cells; and (d) optionally, further fractionating fractions that have tested positive in step (c) and repeating steps (b) and (c) until a homogenous fraction has been identified, said homogenous fraction representing disease-specific molecules; or (b') splitting said body fluids identified in step (a) into at least two portions and depleting one of said portions from cytotoxicity-mediating molecules; (c') subjecting molecules, from said animal or human cells carrying disease-specific molecules to separation techniques that allow an unambiguous identification of each molecule, (d') incubating said separated molecules alternatively with a portion of said body fluid not depleted from said cytotoxicity--mediating molecules and with a portion of said body fluid depleted from said cytotoxicity-mediating molecules; and (e') identifying molecules that are recognized by said portion of said body fluid not depleted from said cytotoxicity-mediating molecules but not by said portion of said body fluid depleted from said cytotoxicity-mediating molecules.
PCT/EP2002/012215 2001-11-02 2002-10-31 Functional identification of targets on tissues and cells Ceased WO2003038439A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP02777339A EP1634080A2 (en) 2001-11-02 2002-10-31 Functional identification of targets on tissues and cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10153584.8 2001-11-02
DE2001153584 DE10153584A1 (en) 2001-11-02 2001-11-02 Procedure for the identification of tumor-specific antigens on cancer cells

Publications (2)

Publication Number Publication Date
WO2003038439A2 WO2003038439A2 (en) 2003-05-08
WO2003038439A3 true WO2003038439A3 (en) 2003-09-25

Family

ID=7704243

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/012215 Ceased WO2003038439A2 (en) 2001-11-02 2002-10-31 Functional identification of targets on tissues and cells

Country Status (3)

Country Link
EP (1) EP1634080A2 (en)
DE (1) DE10153584A1 (en)
WO (1) WO2003038439A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10261086B2 (en) 2013-01-10 2019-04-16 Amrita Vishwa Vidyapeetham Differential cerebrospinal fluid reactivity to PFDN5-alpha for detection of B-cell acute lymphoblastic leukemia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039362A1 (en) * 1997-03-04 1998-09-11 Vander Way Limited Cytotoxic immunoglobulins from mammals
EP1118330A1 (en) * 2000-01-19 2001-07-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Interferon-alpha use in the treatment of Ewing's family of tumors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039362A1 (en) * 1997-03-04 1998-09-11 Vander Way Limited Cytotoxic immunoglobulins from mammals
EP1118330A1 (en) * 2000-01-19 2001-07-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Interferon-alpha use in the treatment of Ewing's family of tumors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HANIBUCHI, M. ET AL: "ANTI-GANGLIOSIDE gm2 MONOCLONAL ANTIBODY-DEPENDENT KILLING OF HUMAN LUNG CANCER CELLS BY LYMPHOCYTES AND MONOCYTES", JPN. J. CAN RES., vol. 87, no. 5, May 1996 (1996-05-01), pages 497 - 504, XP009012455 *
KITAMURA, K. ET AL: "Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine", PROC. NATL. ACAD. SCI., vol. 92, no. 7, March 1995 (1995-03-01), USA, pages 2805 - 2809, XP001147651 *
KOO, P. H.: "Human alpha2-macroglobulin: a major serum factor cytotoxic for tumor cells", CANCER LETTERS, no. 18, 1983, pages 169 - 177, XP009012452 *
OLLERT, M.W. ET AL: "Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells", PROC. NATL. ACAD. SCI., vol. 93, no. 9, 30 April 1996 (1996-04-30), USA, pages 4498 - 4503, XP001147650 *
SCHMITT, C. ET AL: "Natürliche humane IgM-Antikörper in der Therapie des Neuroblastoms: Vorläufige Ergebnisse einer Phase I/II-Therapiestudie", KLINISCHE PÄDIATRIE, vol. 211, 1999, Germany, pages 314 - 318, XP009012433 *

Also Published As

Publication number Publication date
WO2003038439A2 (en) 2003-05-08
EP1634080A2 (en) 2006-03-15
DE10153584A1 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
WO2002053773A3 (en) Method for determining skin stress or skin ageing in vitro
WO2002055740A3 (en) Method for detecting disease associated mutations by means of primer extension
WO2004087887A3 (en) Intracellular complexes as biomarkers
EP1361229A3 (en) Use of Tyrosine Kinase (PYK2) to produce antibodies
WO1998009990A8 (en) Fungal antigens and process for producing the same
WO2007030571A3 (en) Identification of targets and development of reagents for testing and molecular imaging of human disease
WO2003008553A3 (en) Proteins associated with cell growth, differentiation, and death
WO2000044900A3 (en) Nucleic-acid binding proteins
WO2003014322A3 (en) Proteins associated with cell growth, differentiation, and death
WO2003038439A3 (en) Functional identification of targets on tissues and cells
WO2002063951A3 (en) Human disease modeling using somatic gene transfer
WO2002097060A3 (en) Carbohydrate-associated proteins
WO2001085762A3 (en) Cancer diagnosis and assays for screening anti-cancer agents
WO2001079855A3 (en) Method for quantification of akt protein expression
WO2002010363A3 (en) Protein phosphatases
WO2004113566A3 (en) Disease related protein network
WO1999049037A3 (en) Protein phosphatase-related molecules
WO2004016065A3 (en) Immunochromatography system and method for the simultaneous identification of aga and t-tg antibodies and use thereof for the diagnosis of celiac disease
WO1998051782A3 (en) Human 3-hydroxyisobutyryl-coenzyme a hydrolase
WO2002097032A3 (en) Proteins associated with cell growth, differentiation, and death
WO2002054078A3 (en) Method for determining skin ageing in vitro
WO2004031364A3 (en) Proteins associated with cell growth, differentiation, and death
EP1174522A3 (en) TCF-1 nucleotide sequence variation
WO2003095622A8 (en) Proteins associated with cell growth, differentiation, and death
DE50015355D1 (en) PROTEIN MTR1 RELATED TO TRP PROTEINS AND THIS CODING DNA SEQUENCE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NONTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC (EPO FORM 1205A DATED 26.08.2004)

122 Ep: pct application non-entry in european phase
WWE Wipo information: entry into national phase

Ref document number: 2002777339

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002777339

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP